July 2, 2020

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study

Los puntos clave no están disponibles para este artículo en este momento.

Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapy-treated patients with HER2-mutant NSCLC.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Zhou et al. (Thu,) studied this question.

Preguntar a la IA

Me gusta

Guardar